89 / 112
87
WFSBP 2015
Thursday, 18 June 2015
|
Scientific Programme
P-24-020
Translational research of chronic pain patients using human
blood-induced microglia-like (iMG) cells
Masahiro Ohgidani, Japan
T. Kato, M. Hosoi, R. Iwaki, N. Sudo, S. Kanba
P-24-022
Hephaestus revisited: The heritability of lifelong premature
ejaculation
Paddy Janssen, The Netherlands
F. van der Heijden
P-24-024
Impact of non-apnea sleep disorders on diabetic control
and metabolic outcome – a longitudinal cohort study
Ying Chuan Hung, Taiwan
Y.-C. Lin, H.-M. Hsieh, H.-C. Chiu
P-24-025
The quality of life in patients with nonorganic insomnia
Michal Skalski, Poland
A. Król, A. Silka, M. Zarzycki
P-24-026
BDNF concentrations in patients with somatization disorder
before and after treatment
Mal Rye Choi, Republic of Korea
J.-C. Yang, S.-K. Chung, D.-J. Kim, Y.-K. Kim
P-24-027
1) Psychogenic nonepileptic seizures in an epilepsy center
in Colombia: A diagnosis challenge 2) Quality of life in pa-
tients with epilepsy and psychogenic Nnn-epileptic seizures
in a Colombian neurological centre
Maria Alejandra Velez Aguirre, Colombia
P-24-028
Acute adjustment disorders: A descriptive study of 93 pa-
tients
Kilani Hajji, Tunisia
I. Marrag, W. Chebbi, R. Ben Soussia, M. Nasr
P-25
Poster Presentation
12:45–14:15
Muses Foyer
Pharmacological and Brain Stimulation Therapies
Chair:
George Papageorgiou, Greece
Co-Chair: Elena Tsiolka, Greece
P-25-001
30 years after the advent or risperidone–promises and
facts about „atypicals“
Matthias Dose, Germany
P-25-002
Predictors of weight gain during antipsychotic treatment
of schizophrenia
Adam Wysokinski, Poland
R. Magierski, I. Kloszewska, T. Sobów
P-25-003
Efficacy of quetiapine on psychotic symptoms and congni-
tion in Parkinson‘s disease
Gorana Sulejmanpasic-Arslanagic, Bosnia and Herzegovina
S. Fisekovic, A. Kucukalic, S. Ler
P-25-005
Safety profile and weight gain of treatment with risperidone
in patients with schizophrenia
Alma Bravo-Mehmedbasic, Bosnia and Herzegovina
A. Kucukalic, A. Dzubur Kulenovic, S. Kucukalic
P-25-006
Psychiatric pharmacogenomics: A stride in human genetics
and a bridge for individualized treatment
Leslie Kiraly, Canada
Z. Elbaz
P-25-007
Agmatine rescued ASD like behavior in valproic acid in-
duced animal model of autism: New implication for the ASD
Ji-Woon Kim, Republic of Korea
H. Seung, C. s. Choi, H. A. Oh, C. y. Shin
P-25-008
Drug induced body weight gain and metabolic syndrome
in patient with schizophrenia and bipolar disorder
Kyungphil Kwak, Republic of Korea
T. Kim
P-25-009
Influence streptozotocin-induced diabetes on behavioral
activity of offspring and it‘s correction of afobazole
Victoria Zabrodina, Russia
E. Shreder, O. Shreder, A. Durnev
P-25-010
The interaction between decreased short-term spatial mem-
ory and increased oxidative stress in a scopolamine-induced
rat model of Alzheimer‘s disease
Manuela Padurariu, Romania
R. Lefter, A. Ciobica, E. Anton
P-25-011
Psychosis as a side effect of raltegravir
Jose M. Lopez-Santin, Spain
P. Alvaro Seron